SG11201806920SA - Modulation hypoxia associated with stroke - Google Patents

Modulation hypoxia associated with stroke

Info

Publication number
SG11201806920SA
SG11201806920SA SG11201806920SA SG11201806920SA SG11201806920SA SG 11201806920S A SG11201806920S A SG 11201806920SA SG 11201806920S A SG11201806920S A SG 11201806920SA SG 11201806920S A SG11201806920S A SG 11201806920SA SG 11201806920S A SG11201806920S A SG 11201806920SA
Authority
SG
Singapore
Prior art keywords
omniox
international
suite
road
stroke
Prior art date
Application number
SG11201806920SA
Inventor
Moan Natacha Le
Ana Krotolica
Philberta Leung
Stephen Cary
Original Assignee
Omniox Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Omniox Inc filed Critical Omniox Inc
Publication of SG11201806920SA publication Critical patent/SG11201806920SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01H—NEW PLANTS OR NON-TRANSGENIC PROCESSES FOR OBTAINING THEM; PLANT REPRODUCTION BY TISSUE CULTURE TECHNIQUES
    • A01H1/00—Processes for modifying genotypes ; Plants characterised by associated natural traits
    • A01H1/06—Processes for producing mutations, e.g. treatment with chemicals or with radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8216—Methods for controlling, regulating or enhancing expression of transgenes in plant cells
    • C12N15/8218—Antisense, co-suppression, viral induced gene silencing [VIGS], post-transcriptional induced gene silencing [PTGS]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8243—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1085—Transferases (2.) transferring alkyl or aryl groups other than methyl groups (2.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/10—Nitrogen as only ring hetero atom
    • C12P17/12—Nitrogen as only ring hetero atom containing a six-membered hetero ring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
    • C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
    • C12Y101/01247—Codeinone reductase (NADPH) (1.1.1.247)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y205/00—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5)
    • C12Y205/01—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5) transferring alkyl or aryl groups, other than methyl groups (2.5.1)
    • C12Y205/01059—Protein geranylgeranyltransferase type I (2.5.1.59)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Botany (AREA)
  • Developmental Biology & Embryology (AREA)
  • Nutrition Science (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization 111111110111101110101011111010111110111010111111011010111011111111101111011111 International Bureau ... .... ..Yjd (10) International Publication Number (43) International Publication Date ..... ...r .....1 WO 2017/143104 Al 24 August 2017 (24.08.2017) WI P0 I PCT (51) International Patent Classification: (74) Agents: DONAHUE, Brian, A. et al.; Morrison & Foester A61K 38/16 (2006.01) A61P 9/10 (2006.01) LLP, 755 Page Mill Road, Palo Alto, CA 94304-1018 (US). (21) International Application Number: PCT/US2017/018233 (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, (22) International Filing Date: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, 16 February 2017 (16.02.2017) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, (25) Filing Language: English DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, (26) Publication Language: English KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, (30) Priority Data: MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, 62/296,009 16 February 2016 (16.02.2016) US NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, (71) Applicant: OMNIOX, INC. [US/US]; 75 Shoreway Road, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, Suite A, San Carlos, CA 94070-2727 (US). ZA, ZM, ZW. (72) Inventors: LE MOAN, Natacha; C/o Omniox, Inc., 75 (84) Designated States (unless otherwise indicated, for every Shoreway Road, Suite B, San Carlos, CA 94070-2727 kind of regional protection available): ARIPO (BW, GH, (US). KROTOLICA, Ana; C/o Omniox, Inc., 75 Omniox, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, Inc., 75 Shoreway Road, Suite B, San Carlos, CA 94070- TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, 2727 (US). LEUNG, Philberta; C/o Omniox, Inc., 75 TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, Shoreway Road, Suite B, San Carlos, CA 94070-2727 DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, (US). CARY, Stephen, P.L.; C/o Omniox, Inc., 75 Shore- LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, way Road, Suite B, San Carlos, CA 94070-2727 (US). [Continued on next page] = = (54) Title: MODULATION HYPDXIA ASSOCIATED WITH STROKE (57) the delivery of oxygen to hypoxic tissue following stroke. H- : The invention provides H-NOX proteins for . NOX proteins extravasate into hypoxic penumbra associated = with stroke and preferentially accumulate for sustained deliv- FIG. 7B ery of oxygen to the hypoxic tissue to ameliorate adverse af- _ _ — fects of stroke related hypoxia. In some embodiments, the H- NOX comprises PEGylated H-NOX and non-PEGylated H- - ES Infarct NOX. D Hypoxic tissue .E 2 5 ..ow p = 0.05 = . (I) 200 E - 1 — ' T M150 . 0 X100 ' — C — = — CC 50 Veh Veh H-NOXP ,-1 .4 ii- Day 1 Day © ,-1 M ii- ,-1 IN ,-1 © ei O WO 2017/143104 Al 1#110H01101DION01010M010111101101010EM0VOIS SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). with sequence listing part of description (Rule 5.2(a)) Published: — with international search report (Art. 21(3))
SG11201806920SA 2016-02-16 2017-02-16 Modulation hypoxia associated with stroke SG11201806920SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662296009P 2016-02-16 2016-02-16
PCT/US2017/018233 WO2017143104A1 (en) 2016-02-16 2017-02-16 Modulation hypoxia associated with stroke

Publications (1)

Publication Number Publication Date
SG11201806920SA true SG11201806920SA (en) 2018-09-27

Family

ID=58191670

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10202007517TA SG10202007517TA (en) 2016-02-16 2017-02-16 Modulation of hypoxia associated with stroke
SG11201806920SA SG11201806920SA (en) 2016-02-16 2017-02-16 Modulation hypoxia associated with stroke

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10202007517TA SG10202007517TA (en) 2016-02-16 2017-02-16 Modulation of hypoxia associated with stroke

Country Status (15)

Country Link
US (3) US20200276265A1 (en)
EP (1) EP3416673B1 (en)
JP (1) JP2019511567A (en)
KR (1) KR20180123034A (en)
CN (1) CN109069582A (en)
AU (1) AU2017219869A1 (en)
BR (1) BR112018016829A2 (en)
CA (1) CA3014651A1 (en)
DK (1) DK3416673T3 (en)
ES (1) ES2939181T3 (en)
IL (1) IL261178A (en)
MX (1) MX2018009881A (en)
RU (1) RU2018131359A (en)
SG (2) SG10202007517TA (en)
WO (1) WO2017143104A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2897018C (en) * 2013-01-07 2021-07-27 Omniox, Inc. Polymeric forms of h-nox proteins
EP3836911A1 (en) 2018-08-15 2021-06-23 Omniox, Inc. H-nox proteins for treating cardiovascular and pulmonary conditions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
ATE302019T1 (en) 1997-02-28 2005-09-15 Univ California METHOD AND COMPOSITIONS FOR OPTIMIZING OXYGEN TRANSPORT IN CELL-FREE SYSTEMS
JP2005517648A (en) * 2001-12-07 2005-06-16 インターミューン インコーポレイテッド Compositions and methods for treating hepatitis virus infections
US20030153491A1 (en) 2002-01-11 2003-08-14 Winslow Robert M. Methods and compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin
BRPI0711901A2 (en) 2006-05-22 2012-03-06 The Regents Of The University Of California COMPOSITIONS AND METHODS FOR OXYGEN RELEASE
CA2897018C (en) * 2013-01-07 2021-07-27 Omniox, Inc. Polymeric forms of h-nox proteins

Also Published As

Publication number Publication date
SG10202007517TA (en) 2020-09-29
KR20180123034A (en) 2018-11-14
AU2017219869A1 (en) 2018-08-30
RU2018131359A3 (en) 2020-08-12
IL261178A (en) 2018-10-31
US20200276265A1 (en) 2020-09-03
EP3416673A1 (en) 2018-12-26
CN109069582A (en) 2018-12-21
RU2018131359A (en) 2020-03-17
WO2017143104A1 (en) 2017-08-24
EP3416673B1 (en) 2022-11-02
ES2939181T3 (en) 2023-04-19
DK3416673T3 (en) 2023-01-23
US20240026399A1 (en) 2024-01-25
JP2019511567A (en) 2019-04-25
WO2017143104A8 (en) 2018-09-07
MX2018009881A (en) 2019-01-31
BR112018016829A2 (en) 2018-12-26
US20210121521A1 (en) 2021-04-29
CA3014651A1 (en) 2017-08-24

Similar Documents

Publication Publication Date Title
SG11201903882VA (en) Il-2 variants for the treatment of autoimmune diseases
SG11201903857UA (en) Antibodies to pd-1 and uses thereof
SG11201907846VA (en) Therapeutic rna
SG11201908719QA (en) Biomarkers and car t cell therapies with enhanced efficacy
SG11201909949XA (en) Targeted immunotolerance
SG11201804178YA (en) Pd1 and/or lag3 binders
SG11201900480YA (en) Anti-tim-3 antibodies
SG11201808990QA (en) Compositions for topical application of compounds
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201909955XA (en) Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
SG11201806322QA (en) Maytansinoid derivatives, conjugates thereof, and methods of use
SG11201908567UA (en) Modified cyclic dinucleotide compounds
SG11201901716TA (en) Adenovirus armed with bispecific t cell engager (bite)
SG11201810600WA (en) Fxr (nr1h4) modulating compounds
SG11201805137XA (en) Virus encoding an anti-tcr-complex antibody or fragment
SG11201810525XA (en) Anti-gitr antibodies and uses thereof
SG11201407548UA (en) Treatment of amd using aav sflt-1
SG11201804375WA (en) Compositions and methods for internalizing enzymes
SG11201804915RA (en) Methods for treating huntington's disease
SG11201804127SA (en) Ctla4 binders
SG11201806496SA (en) Antigen binding proteins that bind pd-l1
SG11201900200XA (en) Tgfb antibodies, methods, and uses
SG11201907889YA (en) Glycan-interacting compounds and methods of use
SG11201805579SA (en) Recombinant igg fc multimers
SG11201803676PA (en) Site specific her2 antibody drug conjugates